Wednesday, May 08 2024
12:00 PM – 07:00 PM ET - Exhibit Hall
728: Oligonucleotide-Based AML Immunotherapy through Targeted STAT3/DNMT1 Inhibition Combined with TLR9/IRF8 Activation
Marcin Kortylewski - PhD
Beckman Research Institute at City of Hope Comprehensive Cancer Center
Disclosures: M. Kortylewski: 1; Commercial Interest i.e. Company X; Duet Biotherapeutics. 1; What was received? i.e. Honorarium; Sponsored Research Agreement, Honorarium. 1; For what role? i.e. Speaker; Collaborator, Scientific Advisor. 2; Commercial Interest i.e. Company X; Scopus Pharma. 2; What was received? i.e. Honorarium; Honorarium, Royalties. 2; For what role? i.e. Speaker; Scientific Advisor, Inventor. 3; Commercial Interest i.e. Company X; Systems Oncology LLC. 3; What was received? i.e. Honorarium; Royalties. 3; For what role? i.e. Speaker; Inventor.
Related Abstract